教員・教室員について

  1. TOP
  2. 教員・教室員について
  3. 教員・教室員紹介
  4. 教員
  5. 第一内科
  6. 菊繁 吉謙（きくしげ よしかね）

教授

研究教育活動

名前 菊繁吉謙（きくしげ　よしかね）
卒業年 2002（平成14）年
学位取得年月 2011年医学博士学位取得
専門領域 造血器悪性腫瘍
資格 日本内科学会認定内科医、総合内科専門医、指導医
日本血液学会専門医、指導医
所属学会 日本内科学会、日本血液学会、日本輸血細胞治療学会、日本造血細胞移植学会、日本癌学会、日本遺伝性腫瘍学会、日本分子生物学会

略歴

2009年4月

 九州大学病院検査部　医員

2010年4月

 九州大学病院遺伝子細胞療法部　医員

2011年4月

 九州大学病院血液腫瘍内科助教

2012年4月

 日本学術振興会 特別研究員

2016年4月

 応用病態修復学講座 助教
2019年4月

応用病態修復学講座 講師
2020年4月

遺伝子・細胞療法部 講師
2026年4月 病態修復内科学分野（第一内科）教授
現在に至る

代表的業績

  1. Kikushige Y. et al. Late relapse of acute myelogenous leukemia followed by epstein-barr virus-associated lymphoproliferative disease 11 years after allogeneic bone marrow transplantation.
    Int J Hematol 2006; 84: 441-444.
  2. Kikushige Y. et al. Repeated relapses of acute myelogenous leukemia in the isolated extramedullary sites following allogeneic bone marrow transplantations.
    Intern Med 2007; 46: 1011-1014.
  3. Kamezaki K. et al. Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma.
    Bone Marrow Transplant 2007; 39: 523-527.
  4. Kikushige Y. et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival.
    J Immunol 2008; 180: 7358-7367.
  5. Kikushige Y. et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Cell Stem Cell 2010; 7: 708-717.
  6. Kikushige Y. et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia.
    Cancer Cell 2011; 20: 246-59.
  7. Kikushige Y. & Akashi, K. TIM-3 as a therapeutic target for malignant stem cells in acute myelogenous leukemia.
    Ann N Y Acad Sci 2012; 1266: 118-123.
  8. Shima T. et al., Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation.
    Blood 2013; 121: 840-848.
  9. Kikushige Y. & Miyamoto, T. TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.
    Int J Hematol 2013; 98: 627-633.
  10. Damm F. et al., Acquired initiating mutations in early hematopoietic cells of CLL patients.
    Cancer Discov 2014; 4: 1088-1101.
  11. Kikushige Y. & Miyamoto, T. Hematopoietic stem cell aging and chronic lymphocytic leukemia pathogenesis.
    Int J Hematol 2014; 100: 335-340.
  12. Kikushige Y. & Miyamoto, T. Pre-malignant lymphoid cells arise from hematopoietic stem/progenitor cells in chronic lymphocytic leukemia.
    Int J Hematol 2015;
  13. Kikushige Y. et al., A TIM-3/Gal-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemic progression.
    Cell Stem Cell 2015; 17: 341-52.
  14. M. Nakano et al., Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer. Oncogene 38, 780-793 (2019).
  15. Y. Kikushige, Pathophysiology of chronic lymphocytic leukemia and human B1 cell development. Int J Hematol 111, 634-641 (2020).
  16. Y. Kikushige, Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. J Clin Exp Hematop 60, 146-158 (2020).
  17. T. Tochigi et al., Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug-induced thrombocytopenia. Blood 135, 2146-2158 (2020).
  18. Y. Kikushige, TIM-3 in normal and malignant hematopoiesis: Structure, function, and signaling pathways. Cancer Sci 112, 3419-3426 (2021).
  19. K. Hatakeyama et al., TET2 Clonal Hematopoiesis Is Associated With Anthracycline-Induced Cardiotoxicity in Patients With Lymphoma. JACC CardioOncol 4, 141-143 (2022).
  20. T. Sakoda et al., TIM-3 signaling hijacks the canonical Wnt/beta-catenin pathway to maintain cancer stemness in acute myeloid leukemia. Blood Adv 7, 2053-2065 (2023).
  21. T. Harada et al., Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease. Nat Commun 14, 6959 (2023).
  22. Y. Kikushige et al., Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function. Blood Adv 7, 3592-3603 (2023).
  23. K. Hatakeyama et al., Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drugs-induced thromboembolism. Blood Adv,  (2024).

一覧